- Home
- NYXH
NYXH
Nyxoah SA
as 07-26-2024 4:00pm EST
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
| Founded: | 2009 | Country: | Belgium |
| Employees: | N/A | City: | N/A |
| Market Cap: | 236.1M | IPO Year: | 2021 |
| Target Price: | $16.67 | AVG Volume (30 days): | 12.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.00 - $20.00 | Next Earning Date: | 08-06-2024 |
| Revenue: | $5,573,913 | Revenue Growth: | 78.93% |
| Revenue Growth (this year): | 96.25% | Revenue Growth (next year): | 275.73% |
Latest Nyxoah SA News
NYXH Breaking Stock News: Dive into NYXH Ticker-Specific Updates for Smart Investing
MT Newswires
12 days ago
Nyxoah Names Scott Holstine Chief Commercial Officer
GlobeNewswire
12 days ago
Nyxoah Appoints Scott Holstine as Chief Commercial Officer
MT Newswires
23 days ago
Nyxoah Secures $40 Million Loan Facility from European Investment Bank
GlobeNewswire
24 days ago
Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank
MT Newswires
25 days ago
Nyxoah Submits Final Module of Premarket Approval Application for Sleep Apnea Therapy to FDA
GlobeNewswire
a month ago
Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA
GlobeNewswire
a month ago
Information on the total number of voting rights and shares
MT Newswires
a month ago
Stifel Cuts Price Target on Nyxoah to $19 From $27, Maintains Buy Rating
Compare NYXH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NYXH Nyxoah SA - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.